Heald P W, Perez M I, Christensen I, Dobbs N, McKiernan G, Edelson R
Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.
Yale J Biol Med. 1989 Nov-Dec;62(6):629-38.
Over the past two years, the photopheresis treatment program at Yale-New Haven Hospital has treated 32 patients with cutaneous T-cell lymphoma. There were 19 erythrodermic patients who had photopheresis as their first systemic therapy. Five of these cleared 75 percent of their skin and the majority of erythrodermics achieved an improved quality of life. Those with best responses were treated earlier in the course of their disease and had more normal proportions of CD4 and CD8 subsets when compared to patients with poor responses. In addition, patients with tumor stage disease and those patients in relapse after intensive radio- and chemotherapy were treated with photopheresis. These results demonstrate that photopheresis has a role in the management of cutaneous T-cell lymphoma.
在过去两年中，耶鲁-纽黑文医院的光分离置换疗法治疗项目已治疗了32例皮肤T细胞淋巴瘤患者。其中19例红皮病患者将光分离置换疗法作为其首次全身治疗。这些患者中有5例皮肤症状改善了75%，大多数红皮病患者的生活质量得到了提高。与反应不佳的患者相比，反应最佳的患者在疾病进程中接受治疗的时间更早，且CD4和CD8亚群比例更正常。此外，肿瘤期疾病患者以及接受强化放疗和化疗后复发的患者也接受了光分离置换疗法治疗。这些结果表明，光分离置换疗法在皮肤T细胞淋巴瘤的治疗中具有一定作用。
